{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-077853","form_type":"8-K","ticker":"EQ","cik":"0001746466","company_name":"Equillium, Inc.","filed_at":"2023-03-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.392775+00:00","generated_at":"2026-06-17T18:51:36.551723+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Equillium Q4 2022: $15.8M revenue from Ono deal, net income $2.8M; cash $71M into 2025","bullets":["Revenue of $15.8M in Q4 2022 from Ono Pharmaceutical asset purchase agreement; no revenue in prior year period.","Net income of $2.8M ($0.08 per share) in Q4 2022 vs net loss of $10.6M in Q4 2021.","Full year 2022 net loss of $62.4M ($1.85 per share) vs $39.1M loss in 2021, including non-cash in-process R&D from Bioniz acquisition.","Cash, cash equivalents and short-term investments total $71.0M as of Dec 31, 2022; expected to fund operations into 2025.","Partnership with Ono for itolizumab: $26.4M upfront, up to $139M in milestones, and R&D funding."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-077853","json":"https://secwatch.observer/filing/0001193125-23-077853.json","markdown":"https://secwatch.observer/filing/0001193125-23-077853.md","text":"https://secwatch.observer/filing/0001193125-23-077853.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1746466/000119312523077853/0001193125-23-077853-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1746466/000119312523077853/d471634d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T18:51:36.551723+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1b33fa6db5159b868b56e0428e22d5690b18e4b2","claim":"Equillium, Inc. reported the quarter ended December 31, 2022 results: revenue $15.8 million.","evidence_excerpt":"Revenue for the fourth quarter and full year of 2022 was $15.8 million and was derived from the company’s asset purchase agreement with Ono.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1746466/000119312523077853/0001193125-23-077853-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended December 31, 2022"},{"label":"Revenue","value":"$15.8 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"2aa872ffddf7046bafe8b2e8b59e655a985db8c1","claim":"Equillium, Inc. reported the year ended December 31, 2022 results: revenue $15.8 million.","evidence_excerpt":"Revenue for the fourth quarter and full year of 2022 was $15.8 million and was derived from the company’s asset purchase agreement with Ono.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1746466/000119312523077853/0001193125-23-077853-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Revenue","value":"$15.8 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}